Molecular mechanisms for CML resistance to tyrosine kinase inhibitors, beyond point mutations in BCR-ABL kinase domain, still need to be addressed. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.